top of page


The United States has invested billions of dollars in an attempt to understand and prevent Alzheimer's disease. Only 1 out of 244 drugs have been FDA approved to treat Alzheimer's Disease since 2002. Thus, Alzheimer's disease drug candidates have a 99.6% failure rate, compared with 81% for cancer. Moreover, companies have mostly gone after the same target. Unfortunately, the drugs on the market, do little or nothing to help the people suffering from this disease.

Our research will focus on utilizing combination therapies, so that each subpopulation will have access to a unique combination of medicines that are exclusive to the comorbidities* they are dealing with, to ensure maximum protection against future brain damage. 

Inclusivity and diversity are required in order to accurately research and develop drugs for Alzheimer's disease. Having witnessed the success of combination therapy in HIV, cancer and heart disease, the time has come, to attack Alzheimer’s disease on multiple fronts as well. 


Combination therapies have proven to be vitally important in the successful treatment of many patients with cancer and HIV. One study found up to 71% of cancer patients received a minimum of one off-label chemotherapy drug in addition to an "on label" chemotherapy drug, usually in combination with radiation and/or other surgical procedures. In the early 90’s AIDS researchers developed new classes of antiviral medications and eventually began prescribing two or more of these drugs, revealing the most effective combinations. Today, a powerful three-drug antiviral “cocktail” allows people with HIV to live long lives.


When one of the drugs used in combination therapy is already FDA-approved, overall costs of combination therapy research is reduced. This increases cost efficiency of therapy, thereby benefiting the medically underserved

* = Defined Terms

Comorbidities describes other illnesses interacting with Alzheimer's Disease and the effect they may have on the symptoms in an individual with Alzheimer's Disease.

1 in 3

Seniors die with Alzheimer’s or another dementia.

Alzheimer’s disease is officially listed as the sixth-leading cause of death in the United States.

2 in 3

Americans with Alzheimer’s are women.

Of the 5.5 million people age 65 and older with Alzheimer’s in the United States, 3.4 million are women and 2.0 million are men.

Racial difference in the likelihood of Developing Alzheimer's Disease

African-Americans and Hispanics/Latinos are more likely to have Alzheimer’s or other dementias.

African-Americans are about 2x as likely to have Alzheimer’s or other dementias. Hispanics are about 1.5x as likely to have Alzheimer’s or other dementias. 

1 out of 244

Drugs were FDA approved to treat Alzheimer's Disease since 2002. 

This gives Alzheimer's disease drug candidates one of the highest failures rates of any disease area – 99.6%, compared with 81% for cancer.

We Need More Data

From diverse and inclusive population-based cohort studies

Regarding the national prevalence of Alzheimer’s and other dementias with a more accurate representation of racial, ethnic and socioeconomic groups other than whites, African-Americans, and Hispanics. 

bottom of page